The enteric nervous system as a regulator of intestinal epithelial barrier function in health and disease

Expert Review of Gastroenterology and Hepatology

Volumn 4, Issue 5, 2010, Pages 637-651

  Snoek, Susanne A ^a   Verstege, Marleen I ^a   Boeckxstaens, Guy E ^a,b   Van Den Wijngaard, René M ^a   De Jonge, Wouter J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

barrier function; enteric nervous system; enterocyte; inflammatory bowel disease; irritable bowel syndrome; neurotransmitters

Indexed keywords

INTERLEUKIN 6; JUNCTIONAL ADHESION MOLECULE A; MYOSIN LIGHT CHAIN KINASE; PROTEIN ZO1; PROTEIN ZO2; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR;

CELL FUNCTION; CELLULAR STRESS RESPONSE; COLITIS; ENTEROPATHY; GLIA CELL; HUMAN; ILEUS; INTESTINE EPITHELIUM CELL; INTESTINE FUNCTION; INTESTINE INJURY; INTESTINE INNERVATION; INTESTINE PARASITE; MAST CELL DEGRANULATION; MEDIATOR RELEASE; NONHUMAN; PERMEABILITY BARRIER; PROTEIN FUNCTION; REVIEW; TIGHT JUNCTION; VAGUS NERVE STIMULATION;

ENTERIC NERVOUS SYSTEM; EPITHELIAL CELLS; HUMANS; IMMUNITY, MUCOSAL; INFLAMMATION MEDIATORS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; PERMEABILITY;

EID: 77958026197     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.10.51     Document Type: Review

References (120)

1. Groschwitz KR, Hogan SP. Intestinal barrier function: Molecular regulation and disease pathogenesis. J. Allergy Clin. Immunol. 124, 3-20 (2009).
2. Fanning AS, Jameson BJ, Jesaitis LA et al. The tight junction protein ZO-1 establishes a link between the transmembrane protein occludin and the actin cytoskeleton. J. Biol. Chem. 273, 29745-29753 (1998).
3. Itoh M, Furuse M, Morita K et al. Direct binding of three tight junction-associated MAGUKs, ZO-1, ZO-2, and ZO-3, with the COOH termini of claudins. J. Cell. Biol. 147, 1351-1363 (1999).
4. Fanning AS, Anderson JM. Zonula occludens-1 and -2 are cytosolic scaffolds that regulate the assembly of cellular junctions. Ann. N.Y. Acad. Sci. 1165, 113-120 (2009).
5. Marchiando AM, Graham WV, Turner JR. Epithelial barriers in homeostasis and disease. Annu. Rev. Pathol. 5, 119-144 (2010). Overview of the role of tight junctions and role of barrier dysfunction in health and disease.
6. Wittchen ES, Haskins J, Stevenson BR. Protein interactions at the tight junction. Actin has multiple binding partners, and ZO-1 forms independent complexes with ZO-2 and ZO-3. J. Biol. Chem. 274, 35179-35185 (1999).
7. Menard S, Cerf-Bensussan N, Heyman M. Multiple facets of intestinal permeability and epithelial handling of dietary antigens. Mucosal Immunol. 3, 247-259 (2010).
8. Tsukita S, Furuse M, Itoh M. Multifunctional strands in tight junctions. Nat. Rev. Mol. Cell. Biol. 2, 285-293 (2001).
9. Furuse M, Hirase T, Itoh M et al. Occludin: A novel integral membrane protein localizing at tight junctions. J. Cell. Biol. 123, 1777-1788 (1993). Describes the discovery of occludin, an important breakthrough in identification of structure and function of the tight junction (TJs).
10. Furuse M, Fujita K, Hiiragi T et al. Claudin-1 and -2: Novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J. Cell. Biol. 141, 1539-1550 (1998).
11. Heiskala M, Peterson PA, Yang Y. The roles of claudin superfamily proteins in paracellular transport. Traffic 2, 93-98 (2001).
12. Martin-Padura I, Lostaglio S, Schneemann M et al. Junctional adhesion molecule, a novel member of the immunoglobulin superfamily that distributes at intercellular junctions and modulates monocyte transmigration. J. Cell. Biol. 142, 117-127 (1998).
13. Andreeva AY, Krause E, Muller EC et al. Protein kinase C regulates the phosphorylation and cellular localization of occludin. J. Biol. Chem. 276, 38480-38486 (2001).
14. Clarke H, Soler AP, Mullin JM. Protein kinase C activation leads to dephosphorylation of occludin and tight junction permeability increase in LLC-PK1 epithelial cell sheets. J. Cell. Sci. 113 (Pt 18), 3187-3196 (2000).
15. Sakakibara A, Furuse M, Saitou M et al. Possible involvement of phosphorylation of occludin in tight junction formation. J. Cell. Biol. 137, 1393-1401 (1997). (Pubitemid 27265950)
16. Saitou M, Fujimoto K, Doi Y et al. Occludin-deficient embryonic stem cells can differentiate into polarized epithelial cells bearing tight junctions. J. Cell. Biol. 141, 397-408 (1998).
17. Saitou M, Furuse M, Sasaki H et al. Complex phenotype of mice lacking occludin, a component of tight junction strands. Mol. Biol. Cell. 11, 4131-4142 (2000).
18. Barrios-Rodiles M, Brown KR, Ozdamar B et al. High-throughput mapping of a dynamic signaling network in mammalian cells. Science 307, 1621-1625 (2005).
19. Inai T, Kobayashi J, Shibata Y. Claudin-1 contributes to the epithelial barrier function in MDCK cells. Eur. J. Cell. Biol. 78, 849-855 (1999).
20. Van IC, Rahner C, Anderson JM. Regulated expression of claudin-4 decreases paracellular conductance through a selective decrease in sodium permeability. J. Clin. Invest. 107, 1319-1327 (2001).
21. Bruewer M, Luegering A, Kucharzik T et al. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J. Immunol. 171, 6164-6172 (2003).
22. Zolotarevsky Y, Hecht G, Koutsouris A et al. A membrane-permeant peptide that inhibits MLC kinase restores barrier function in in vitro models of intestinal disease. Gastroenterology 123, 163-172 (2002).
23. Al-Sadi R, Ye D, Dokladny K et al. Mechanism of IL-1b-induced increase in intestinal epithelial tight junction permeability. J. Immunol. 180, 5653-5661 (2008).
24. Al-Sadi R, Boivin M, Ma T. Mechanism of cytokine modulation of epithelial tight junction barrier. Front. Biosci. 14, 2765-2778 (2009). Reviews the molecular effects of cytokines on TJ barrier and mechanisms that mediate modulation of TJ by cytokines.
25. Boivin MA, Roy PK, Bradley A et al. Mechanism of interferon-g-induced increase in T84 intestinal epithelial tight junction. J. Interferon Cytokine Res. 29, 45-54 (2009).
26. Anderson JM, van Itallie CM. Tight junctions and the molecular basis for regulation of paracellular permeability. Am. J. Physiol. 269, G467-G475 (1995).
27. Hecht G, Pestic L, Nikcevic G et al. Expression of the catalytic domain of myosin light chain kinase increases paracellular permeability. Am. J. Physiol. 271, C1678-C1684 (1996).
28. Turner JR. Intestinal mucosal barrier function in health and disease. Nat. Rev. Immunol. 9, 799-809 (2009).
29. Weber CR, Raleigh DR, Su L et al. Epithelial myosin light chain kinase activation induces mucosal interleukin-13 expression to alter tight junction ion selectivity. J. Biol. Chem. 285, 12037-12046 (2010).
30. Al-Sadi RM, Ma TY. IL-1b causes an increase in intestinal epithelial tight junction permeability. J. Immunol. 178, 4641-4649 (2007).
31. Ma TY, Boivin MA, Ye D et al. Mechanism of TNF-α modulation of Caco-2 intestinal epithelial tight junction barrier: Role of myosin light-chain kinase protein expression. Am. J. Physiol. Gastrointest. Liver Physiol. 288, G422-G430 (2005).
32. Schulzke JD, Bojarski C, Zeissig S et al. Disrupted barrier function through epithelial cell apoptosis. Ann. N.Y. Acad. Sci. 1072, 288-299 (2006).
33. Jin X, Zimmers TA, Zhang Z et al. Interleukin-6 is an important in vivo inhibitor of intestinal epithelial cell death in mice. Gut 59(2), 186-196 (2010).
34. Cario E. Innate immune signalling at intestinal mucosal surfaces: A fine line between host protection and destruction. Curr. Opin. Gastroenterol. 24, 725-732 (2008).
35. Ey B, Eyking A, Gerken G et al. TLR2 mediates gap junctional intercellular communication through connexin-43 in intestinal epithelial barrier injury. J. Biol. Chem. 284, 22332-22343 (2009).
36. Zhang Q, Li Q, Wang C et al. Enteropathogenic Escherichia coli changes distribution of occludin and ZO-1 in tight junction membrane microdomains in vivo. Microb. Pathog. 48(1), 28-34 (2010).
37. Wine E, Ossa JC, Gray-Owen SD et al. Adherent-invasive Escherichia coli, strain LF82 disrupts apical junctional complexes in polarized epithelia. BMC Microbiol. 9, 180 (2009).
38. Kohler H, Sakaguchi T, Hurley BP et al. Salmonella enterica serovar Typhimurium regulates intercellular junction proteins and facilitates transepithelial neutrophil and bacterial passage. Am. J. Physiol. Gastrointest. Liver Physiol. 293, G178-G187 (2007).
39. Chen ML, Ge Z, Fox JG et al. Disruption of tight junctions and induction of proinflammatory cytokine responses in colonic epithelial cells by Campylobacter jejuni. Infect. Immun. 74, 6581-6589 (2006).
40. Moorthy G, Murali MR, Devaraj SN. Lactobacilli facilitate maintenance of intestinal membrane integrity during Shigella dysenteriae 1 infection in rats. Nutrition 25, 350-358 (2009).
41. Johnson-Henry KC, Donato KA, Shen-Tu G et al. Lactobacillus rhamnosus strain GG prevents enterohemorrhagic Escherichia coli O157:H7-induced changes in epithelial barrier function. Infect. Immun. 76, 1340-1348 (2008).
42. Favier C, Neut C, Mizon C et al. Fecal β-D-galactosidase production and Bifidobacteria are decreased in Crohn's disease. Dig. Dis. Sci. 42, 817-822 (1997).
43. Swidsinski A, Ladhoff A, Pernthaler A et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 122, 44-54 (2002).
44. Zeissig S, Burgel N, Gunzel D et al. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease. Gut 56, 61-72 (2007).
45. Kucharzik T, Walsh SV, Chen J et al. Neutrophil transmigration in inflammatory bowel disease is associated with differential expression of epithelial intercellular junction proteins. Am. J. Pathol. 159, 2001-2009 (2001).
46. Laukoetter MG, Nava P, Lee WY et al. JAM-A regulates permeability and inflammation in the intestine in vivo. J. Exp. Med. 204, 3067-3076 (2007).
47. Vetrano S, Rescigno M, Cera MR et al. Unique role of junctional adhesion molecule-a in maintaining mucosal homeostasis in inflammatory bowel disease. Gastroenterology 135, 173-184 (2008).
48. Marshall JS. Mast-cell responses to pathogens. Nat. Rev. Immunol. 4, 787-799 (2004).
49. Bischoff SC, Lorentz A, Schwengberg S et al. Mast cells are an important cellular source of tumour necrosis factor a in human intestinal tissue. Gut 44, 643-652 (1999).
50. Oprins JC, van der Burg C, Meijer HP et al. Tumour necrosis factor a potentiates ion secretion induced by histamine in a human intestinal epithelial cell line and in mouse colon: Involvement of the phospholipase D pathway. Gut 50, 314-321 (2002).
51. Jacob C, Yang PC, Darmoul D et al. Mast cell tryptase controls paracellular permeability of the intestine. Role of protease-activated receptor 2 and b-arrestins. J. Biol. Chem. 280, 31936-31948 (2005).
52. Cenac N, Chin AC, Garcia-Villar R et al. PAR2 activation alters colonic paracellular permeability in mice via IFN-g-dependent and -independent pathways. J. Physiol. 558, 913-925 (2004).
53. Scudamore CL, Jepson MA, Hirst BH et al. The rat mucosal mast cell chymase, RMCP-II, alters epithelial cell monolayer permeability in association with altered distribution of the tight junction proteins ZO-1 and occludin. Eur. J. Cell. Biol. 75, 321-330 (1998).
54. Sharma R, Prasad V, McCarthy ET et al. Chymase increases glomerular albumin permeability via protease-activated receptor-2. Mol. Cell. Biochem. 297, 161-169 (2007).
55. Taylor CT, Keely SJ. The autonomic nervous system and inflammatory bowel disease. Auton. Neurosci. 133, 104-114 (2007).
56. Furness JB. Types of neurons in the enteric nervous system. J. Auton. Nerv. Syst. 81, 87-96 (2000).
57. Ruhl A. Glial cells in the gut. Neurogastroenterol. Motil. 17, 777-790 (2005). Descriptive review on the role and characteristics of enteric glial cells (EGCs).
58. Genton L, Kudsk KA. Interactions between the enteric nervous system and the immune system: Role of neuropeptides and nutrition. Am. J. Surg. 186, 253-258 (2003).
59. Bush TG, Savidge TC, Freeman TC et al. Fulminant jejuno-ileitis following ablation of enteric glia in adult transgenic mice. Cell 93, 189-201 (1998). Demonstrates for the first time that EGCs are crucial in the regulation of the epithelial barrier and identifies EGC-secreted GNSO as a crucial factor in maintaining intestinal barrier function.
60. Savidge TC, Newman P, Pothoulakis C et al. Enteric glia regulate intestinal barrier function and inflammation via release of S- nitrosoglutathione. Gastroenterology 132, 1344-1358 (2007).
61. Seidlitz EP, Sharma MK, Singh G. A by-product of glutathione production in cancer cells may cause disruption in bone metabolic processes. Can. J. Physiol. Pharmacol. 88, 197-203 (2010).
62. Aube AC, Cabarrocas J, Bauer J et al. Changes in enteric neurone phenotype and intestinal functions in a transgenic mouse model of enteric glia disruption. Gut 55, 630-637 (2006).
63. Neunlist M, Aubert P, Bonnaud S et al. Enteric glia inhibit intestinal epithelial cell proliferation partly through a TGF-b1-dependent pathway. Am. J. Physiol. Gastrointest. Liver Physiol. 292, G231-G241 (2007).
64. Van LL, Mahe MM, Teusan R et al. Regulation of intestinal epithelial cells transcriptome by enteric glial cells: Impact on intestinal epithelial barrier functions. BMC Genomics 10, 507 (2009).
65. Abdo H, Derkinderen P, Gomes P et al. Enteric glial cells protect neurons from oxidative stress in part via reduced glutathione. FASEB J. 24(4), 1082-1094 (2009).
66. Van Der Zanden EP, Boeckxstaens GE, de Jonge WJ. The vagus nerve as a modulator of intestinal inflammation. Neurogastroenterol. Motil. 21, 6-17 (2009). Comprehensive review on all aspects of modulation of the intestinal immune response by the vagus nerve.
67. Luyer MD, Greve JW, Hadfoune M et al. Nutritional stimulation of cholecystokinin receptors inhibits inflammation via the vagus nerve. J. Exp. Med. 202, 1023-1029 (2005).
68. de Haan JJ, Lubbers T, Hadfoune M et al. Postshock intervention with high-lipid enteral nutrition reduces inflammation and tissue damage. Ann. Surg. 248, 842-848 (2008).
69. Ghia JE, Blennerhassett P, Kumar-Ondiveeran H et al. The vagus nerve: A tonic inhibitory influence associated with inflammatory bowel disease in a murine model. Gastroenterology 131, 1122-1130 (2006).
70. Ghia JE, Blennerhassett P, El-Sharkawy RT et al. The protective effect of the vagus nerve in a murine model of chronic relapsing colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 293, G711-G718 (2007).
71. Boeckxstaens GE, de Jonge WJ. Neuroimmune mechanisms in postoperative ileus. Gut 58, 1300-1311 (2009).
72. Van Der Zanden EP, Snoek SA, Heinsbroek SE et al. Vagus nerve activity augments intestinal macrophage phagocytosis via nicotinic acetylcholine receptor α4β2. Gastroenterology 137, 1029-1039 (2009).
73. Wu R, Dong W, Qiang X et al. Orexigenic hormone ghrelin ameliorates gut barrier dysfunction in sepsis in rats. Crit. Care Med. 37, 2421-2426 (2009).
74. Yuan PQ, Kimura H, Million M et al. Central vagal stimulation activates enteric cholinergic neurons in the stomach and VIP neurons in the duodenum in conscious rats. Peptides 26, 653-664 (2005).
75. Kirchgessner AL, Gershon MD. Identification of vagal efferent fibers and putative target neurons in the enteric nervous system of the rat. J. Comp. Neurol. 285, 38-53 (1989).
76. Dahlstrand C, Theodorsson E, Dahlstrom A et al. VIP antisera inhibit the relaxatory motor responses of the feline sphincter of Oddi and gall-bladder induced by VIP or vagal nerve stimulation. Acta Physiol. Scand. 137, 375-378 (1989).
77. Neunlist M, Toumi F, Oreschkova T et al. Human ENS regulates the intestinal epithelial barrier permeability and a tight junction-associated protein ZO-1 via VIPergic pathways. Am. J. Physiol. Gastrointest. Liver Physiol. 285, G1028-G1036 (2003).
78. Wessler I, Kirkpatrick CJ. Acetylcholine beyond neurons: The non-neuronal cholinergic system in humans. Br. J. Pharmacol. 154, 1558-1571 (2008).
79. Snoek SA, Borensztajn KS, van den Wijngaard RM et al. Neuropeptide receptors in intestinal disease: Physiology and therapeutic potential. Curr. Pharm. Des. 16(9), 1091-1105 (2010).
80. Gulbransen BD, Sharkey KA. Purinergic neuron-to-glia signaling in the enteric nervous system. Gastroenterology 136, 1349-1358 (2009).
81. Farre R, De VR, Geboes K et al. Critical role of stress in increased oesophageal mucosa permeability and dilated intercellular spaces. Gut 56, 1191-1197 (2007).
82. Mawdsley JE, Rampton DS. The role of psychological stress in inflammatory bowel disease. Neuroimmunomodulation 13, 327-336 (2006).
83. Tache Y, Kiank C, Stengel A. A role for corticotropin-releasing factor in functional gastrointestinal disorders. Curr. Gastroenterol. Rep. 11, 270-277 (2009).
84. Gareau MG, Silva MA, Perdue MH. Pathophysiological mechanisms of stress-induced intestinal damage. Curr. Mol. Med. 8, 274-281 (2008).
85. van den Wijngaard RM, Klooker TK, de Jonge WJ et al. Peripheral relays in stress-induced activation of visceral afferents in the gut. Auton. Neurosci. 153, 99-105 (2010).
86. Soderholm JD, Yang PC, Ceponis P et al. Chronic stress induces mast cell-dependent bacterial adherence and initiates mucosal inflammation in rat intestine. Gastroenterology 123, 1099-1108 (2002).
87. Lievin-Le Moal, V, Servin AL. The front line of enteric host defense against unwelcome intrusion of harmful microorganisms: Mucins, antimicrobial peptides, and microbiota. Clin. Microbiol. Rev. 19, 315-337 (2006).
88. Castagliuolo I, Wershil BK, Karalis K et al. Colonic mucin release in response to immobilization stress is mast cell dependent. Am. J. Physiol. 274, G1094-G1100 (1998).
89. Wood JD. Histamine, mast cells, and the enteric nervous system in the irritable bowel syndrome, enteritis, and food allergies. Gut 55, 445-447 (2006).
90. Quigley EM. Bacterial flora in irritable bowel syndrome: Role in pathophysiology, implications for management. J. Dig. Dis. 8, 2-7 (2007).
91. Saunders PR, Miceli P, Vallance BA et al. Noradrenergic and cholinergic neural pathways mediate stress-induced reactivation of colitis in the rat. Auton. Neurosci. 124, 56-68 (2006).
92. Farhadi A, Fields JZ, Keshavarzian A. Mucosal mast cells are pivotal elements in inflammatory bowel disease that connect the dots: Stress, intestinal hyperpermeability and inflammation. World J. Gastroenterol. 13, 3027-3030 (2007).
93. Pfeiffer CJ, Qiu B, Lam SK. Reduction of colonic mucus by repeated short-term stress enhances experimental colitis in rats. J. Physiol. Paris 95, 81-87 (2001).
94. Ponferrada A, Caso JR, Alou L et al. The role of PPARg on restoration of colonic homeostasis after experimental stress-induced inflammation and dysfunction. Gastroenterology 132, 1791 - 1803 (2007).
95. Piche T, Barbara G, Aubert P et al. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: Involvement of soluble mediators. Gut 58, 196-201 (2009).
96. Barbara G, Wang B, Stanghellini V et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 132, 26-37 (2007).
97. Alonso C, Guilarte M, Vicario M et al. Maladaptive intestinal epithelial responses to life stress may predispose healthy women to gut mucosal inflammation. Gastroenterology 135, 163-172 (2008).
98. Ait-Belgnaoui A, Bradesi S, Fioramonti J et al. Acute stress-induced hypersensitivity to colonic distension depends upon increase in paracellular permeability: Role of myosin light chain kinase. Pain 113, 141-147 (2005).
99. Demaude J, Leveque M, Chaumaz G et al. Acute stress increases colonic paracellular permeability in mice through a mast cell-independent mechanism: Involvement of pancreatic trypsin. Life Sci. 84, 847-852 (2009).
100. Geboes K, Collins S. Structural abnormalities of the nervous system in Crohn's disease and ulcerative colitis. Neurogastroenterol. Motil. 10, 189-202 (1998).
101. Neunlist M, Aubert P, Toquet C et al. Changes in chemical coding of mysenteric neurones in ulcerative colitis. Gut 52, 84-90 (2003).
102. Thuijls G, de Haan JJ, Derikx JP et al. Intestinal cytoskeleton degradation precedes tight junction loss following hemorrhagic shock. Shock 31, 164-169 (2009).
103. Mittal A, Phillips AR, Loveday B et al. The potential role for xanthine oxidase inhibition in major intra-abdominal surgery. World J. Surg. 32, 288-295 (2008).
104. Anup R, Susama P, Balasubramanian KA. Role of xanthine oxidase in small bowel mucosal dysfunction after surgical stress. Br. J. Surg. 87, 1094-1101 (2000).
105. Ramachandran A, Patra S, Balasubramanian KA. Intestinal mitochondrial dysfunction in surgical stress. J. Surg. Res. 99, 120-128 (2001).
106. Lewis K, McKay DM. Metabolic stress evokes decreases in epithelial barrier function. Ann. N.Y. Acad. Sci. 1165, 327-337 (2009).
107. Holland J, Carey M, Hughes N et al. Intraoperative splanchnic hypoperfusion, increased intestinal permeability, down-regulation of monocyte class II major histocompatibility complex expression, exaggerated acute phase response, and sepsis. Am. J. Surg. 190, 393-400 (2005).
108. Gatt M, Reddy BS, MacFie J. Review article: Bacterial translocation in the critically ill - evidence and methods of prevention. Aliment. Pharmacol. Ther. 25, 741-757 (2007).
109. MacFie J, Reddy BS, Gatt M et al. Bacterial translocation studied in 927 patients over 13 years. Br. J. Surg. 93, 87-93 (2006).
110. MacFie J. Current status of bacterial translocation as a cause of surgical sepsis. Br. Med. Bull. 71, 1-11 (2004).
111. Balzan S, de Almeida QC, de CR et al. Bacterial translocation: Overview of mechanisms and clinical impact. J. Gastroenterol. Hepatol. 22, 464-471 (2007).
112. Buchholz BM, Chanthaphavong RS, Bauer AJ. Nonhemopoietic cell TLR4 signaling is critical in causing early lipopolysaccharide-induced ileus. J. Immunol. 183, 6744-6753 (2009).
113. Derikx JP, van Waardenburg DA, Thuijls G et al. New insight in loss of gut barrier during major non-abdominal surgery. PLoS One 3, e3954 (2008).
114. Ben-Horin S, Chowers Y. Neuroimmunology of the gut: Physiology, pathology, and pharmacology. Curr. Opin. Pharmacol. 8, 490-495 (2008).
115. Conlin VS, Wu X, Nguyen C et al. Vasoactive intestinal peptide ameliorates intestinal barrier disruption associated with Citrobacter rodentium-induced colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 297(4). 6735-6750 (2009).
116. Luyer MD, Buurman WA, Hadfoune M et al. Pretreatment with high-fat enteral nutrition reduces endotoxin and tumor necrosis factor-a and preserves gut barrier function early after hemorrhagic shock. Shock 21, 65-71 (2004).
117. Snoek SA, Verstege MI, van Der Zanden EP et al. Selective α7 nicotinic acetylcholine receptor agonists worsen disease in experimental colitis. Br. J. Pharmacol. 160, 322-333 (2010).
118. Sykes AP, Brampton C, Klee S et al. An investigation into the effect and mechanisms of action of nicotine in inflammatory bowel disease. Inflamm. Res. 49, 311-319 (2000).
119. McGrath J, McDonald JW, Macdonald JK. Transdermal nicotine for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev. CD004722 (2004).
120. Furlan R, Ardizzone S, Palazzolo L et al. Sympathetic overactivity in active ulcerative colitis: Effects of clonidine. Am. J. Physiol. Regul. Integr. Comp. Physiol. 290, R224-R232 (2006). Demonstrates for the first time that EGCs are crucial in the regulation of the epithelial barrier and identifies EGC-secreted GNSO as a crucial factor in maintaining intestinal barrier function.